Skip to main content
(from left to right): Fabian Kienbaum, Fiona Adshead, Michael Moser, Anahita Thoms, Judith Walls
Download Image (JPG 6111KB)

The Fresenius healthcare group has appointed an independent advisory board for sustainability issues. Four leading international experts from science, business, and consulting will in future support Fresenius in further development of its sustainability strategy. They will advise Michael Moser, who is the Management Board member responsible for environmental, social and governance (ESG).

"As a leading healthcare company, we contribute with our products and services to improving access to high-quality healthcare. We see it as our responsibility to lead by example when it comes to environment, social, and governance. Consistent further development of our ESG agenda is therefore an integral part of our #FutureFresenius strategy. This is how we fulfill our corporate purpose of advancing patient care," said Michael Sen, CEO of Fresenius.

"Together with the newly established sustainability advisory board, we are working on a concrete sustainability plan for the next five years. We want to set new priorities within the company and find answers to the most pressing questions of our time. I am very much looking forward to further expanding our expertise in this crucial area and to working together with leading as well as inspiring advisors," said Michael Moser.

The ESG Advisory Board is going to aid in developing the company’s ESG program further. Its members are extremely knowledgeable in Fresenius' key areas of action in the field of sustainability: from the design and implementation of health concepts and climate protection, through corporate sustainability principles, to future-oriented management and sustainable leadership as well as sustainability transformation.

Fresenius is making good progress in the area of sustainability: It reduced its CO2 emissions by 22 percent compared to the base year of 2020, for example. Fresenius is thus on track to halve its CO2 emissions by 2030 and to be climate neutral by 2040. In order to achieve health equity and enable equal opportunities in healthcare even more efficiently, Fresenius committed to the World Economic Forum's Zero Health Gaps Pledge at the beginning of the year. Fresenius thus commits, among other companies and organizations, to acting responsibly for equal opportunities in healthcare.

The ESG Advisory Board consists of the following members:

  • Anahita Thoms (chairwoman): Anahita Thoms leads Baker McKenzie's international trade practice in Germany and is a member of the EMEA Steering Committee für Compliance & Investigations. She is Global Lead Sustainability Partner for the Industrials, Manufacturing & Transportation industry group. She holds a seat on the National Committee of UNICEF Germany and the Board of Atlantik-Brücke. She has also been a member of the German government's Sustainable Finance Advisory Committee and the American Bar Association's International Human Rights Steering Committee.
  • Fiona Adshead: Fiona Adshead is the former Deputy Chief Medical Officer in the UK Government and a leading expert on sustainability and health. She currently chairs the Sustainable Healthcare Coalition, an organization that brings partners together to promote sustainable healthcare. 
  • Fabian Kienbaum: Fabian Kienbaum has been a managing partner in the third generation at Kienbaum since 2014 and has co-led the company together with Dr. Bibi Hahn since 2021. He focuses on advising family businesses on corporate governance and succession planning, and is the author of numerous publications on leadership and New Work.
  • Prof. Judith Walls: Judith Walls is Chair of Sustainability Management and Director of the Institute for Economy and the Environment at the University of St. Gallen. She conducts research at the intersection between business and environmental sustainability.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. 
Fresenius does not undertake any responsibility to update the forward-looking statements in this release.